1. Leading 20 therapeutic classes by U. S. sales, MAT, June 2004. IMS Health. IMS National Sales Perspectives, August 2004. Disponible en: http://www.imshealth.com
2. Hipertensión arterial en México: resultados de la Encuesta Nacional de Salud (ENSA) 2000;Velázquez;Arch Cardiol Méx,2002
3. Risk of cardiovascular events associated with selective COX-2-inhibitors;Mukherjee;JAMA,2001
4. COX-2 and beyond: approaches to prostaglandin inhibition in human disease;FitzGerald;Nat Rev Drug Discov,2003
5. Guidelines Subcommittee;1999 World Health Organization — International Society of Hypertension Guidelines for the Management of Hypertension;J Hypertens.,1999